British Journal of Haematology最新文献

{"title":"Relevance of anti-thyroperoxidase antibodies in immune thrombocytopenia in adults: A single-centre cohort study.","authors":"Nicolas Duhamel, Marie Ottavi, Sarah Lechtman, Nihal Martis, Charlotte Hinault-Boyer, Julie Merindol, Pierre-Yves Jeandel, Michael Levraut","doi":"10.1111/bjh.70745","DOIUrl":"10.1111/bjh.70745","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1941-1944"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial.","authors":"Dana L Casey, Lindsay A Renfro, Yue Wu, Kathleen McCarten, Qinglin Pei, Sarah A Milgrom, Jennifer A Belsky, Steve Cho, Frank G Keller, Angela Punnett, David C Hodgson, Bradford S Hoppe, Kara M Kelly, Sharon M Castellino","doi":"10.1111/bjh.70625","DOIUrl":"10.1111/bjh.70625","url":null,"abstract":"<p><p>Outcomes for high-risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra-nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2-21 years with high-risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE-PC) versus Bv-AVEPC. Patients with stage IV disease, determined by protocol-defined and centrally reviewed Positron Emission Tomography - Computed Tomography (PET-CT), were identified. Baseline characteristics and progression-free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE-PC and 167 (49%) Bv-AVEPC. PFS was highest with lung-only involvement (4-year PFS 88.6%) and lowest with bone marrow-only involvement (4-year PFS 71.9%). Compared to ABVE-PC, Bv-AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33-0.85) and in the lung-only and bone-only subgroups. However, no PFS benefit was observed in those with bone marrow-only involvement. Among paediatric patients with stage IV cHL, Bv-AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1746-1753"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148409738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.","authors":"Desiree Kunadt, Sven Zukunft, Christoph Röllig, Stephan Metzelder, Andreas Burchert, Eva Wagner-Drouet, Oliver Kriege, Christoph Schliemann, Matthias Stelljes, Julian Ronnacker, Wolfgang Bethge, Jan Frederic Weller, Björn Steffen, Gesine Bug, Khouloud Kouidri, Claudia Baldus, Lars Fransecky, Elisa Sala, Uwe Platzbecker, Klaus Metzeler, Sabine Kayser, Inken Hilgendorf, Andreas Hochhaus, Tim H Brümmendorf, Edgar Jost, Anna Dorottya Doleschall, Thomas Schroeder, Jennifer Kaivers, Lambros Kordelas, Udo Holtick, Julia M Unglaub, Tim Sauer, Paul Sebastian Jäger, Guido Kobbe, Elena Stauffer, Johanna Tischer, Tobias Herold, Normann Steiner, David Nachbaur, Nicolaus Kröger, Jochen J Frietsch, Sabrina Kraus, Hermann Einsele, Mathias Hänel, Judith Schaffrath, William Krüger, Anne Brandenburg, Tobias A W Holderried, Laura Reinhardt, Markus Maulhardt, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Jan M Middeke, Friedrich Stölzel","doi":"10.1111/bjh.70735","DOIUrl":"10.1111/bjh.70735","url":null,"abstract":"<p><p>Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second-generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real-world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3-internal tandem duplication and/or FLT3-tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1-year OS of 34%, while those with consolidating alloHSCT had a 1-year OS of 76%-92%, depending on gilteritinib maintenance post-transplant. Resuming gilteritinib post-transplant led to an 85.7% CR/CRi rate. Our real-world data confirm that gilteritinib is an effective single-agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post-transplant maintenance.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1783-1796"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.","authors":"Rory M Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F Little, Steven D Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S Bindra, Amer M Zeidan, Stephanie Halene","doi":"10.1111/bjh.70756","DOIUrl":"10.1111/bjh.70756","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1891-1895"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donor age as a dual-risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation.","authors":"Satoshi Nishiwaki, Yoshiko Atsuta, Ryu Yanagisawa, Hideki Nakasone, Takashi Nagayama, Fumiya Wada, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Tetsuya Nishida, Yuta Hasegawa, Noboru Asada, Masashi Sawa, Jun Ishikawa, Toshiro Kawakita, Tetsuya Eto, Yoshinobu Kanda, Moeko Hino, Kazuhiko Ikeda, Junya Kanda, Ken Tabuchi, Koichi Miyamura, Koji Kato, Yasuo Morishima, Shingo Yano, Yoshihisa Kodera","doi":"10.1111/bjh.70707","DOIUrl":"10.1111/bjh.70707","url":null,"abstract":"<p><p>Donor selection in allogeneic haematopoietic stem cell transplantation (allo-HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual-association donor factors (DADFs)-donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival-using umbilical cord blood (UCB) as a donor-safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013-2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)-adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post-transplant cyclophosphamide (OD-PTCy-Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW-adjusted analyses, allo-HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse-free survival (RFS) compared with UCB. In PSM analyses of elderly high-risk recipients, OD-PTCy-Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high-risk settings.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1797-1806"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148589499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An early integrated prognostic system for predicting relapse and guiding intervention post-CD19 CAR-T therapy in B-cell acute lymphoblastic leukaemia.","authors":"Jiamin Yao, Qing Zhang, Huiping Wang, Fan Wu, Yingwei Li, Lili Tao, Caixian Xu, Jiyu Wang, Wanqiu Zhang, Zhitao Wang, Weiwei Zhu, Zhimin Zhai, Furun An, Qianshan Tao","doi":"10.1111/bjh.70715","DOIUrl":"10.1111/bjh.70715","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1896-1900"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148576178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic heamatopoietic stem cell transplant in patients with refractory T-cell large granular lymphocytic leukaemia: A single-centre experience.","authors":"Paolo Lopedote, Lauren Epler-Tagliaferro, Matthew G Mei, Sunmin Park, Annie Xiao, Idoroenyi Amanam, Salman Otoukesh, Guido Marcucci, Monzr M Al Malki, Ryotaro Nakamura, Vinod Pullarkat","doi":"10.1111/bjh.70750","DOIUrl":"10.1111/bjh.70750","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1928-1931"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study.","authors":"Guillaume Escure, Corinne Frere, Naella Lamamra, Benjamin Crichi, Laurent Frenzel, Salomon Manier, Emilie Chalayer","doi":"10.1111/bjh.70731","DOIUrl":"10.1111/bjh.70731","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1886-1890"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predict less, prevent more: A familiar mantra for sickle cell anaemia?","authors":"Charles T Quinn","doi":"10.1111/bjh.70725","DOIUrl":"10.1111/bjh.70725","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1974-1976"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148596980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes'.","authors":"Yilin Chen, Xiaotong Zhang, Na Shen, Jianguang Zhang, Rong Guo, Haizhou Xing, Lijie Han, Yi Liu, Wenliang Tian, Meng Wang, Xinsheng Xie, Zhongxing Jiang, Dingming Wan, Xuefang Zhou, Huili Xu, Ling Qin, Wei Shi, Weijie Cao, Zhilei Bian","doi":"10.1111/bjh.70670","DOIUrl":"10.1111/bjh.70670","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":"1964-1965"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}